ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v9i4.390ppharm-302Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESФАРМАКОЭКОНОМИЧЕСКИЕ АСПЕКТЫ ТЕРАПИИ ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТА АДАЛИМУМАБОМPHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITISСимпсонК.SimpsonK.neonatepearl@yandex.ruМарлоуН.MarlowN.neonatepearl@yandex.ruШоуДж.ShawJ.neonatepearl@yandex.ruРудаковаА. В.RudakovaА. V.rudakova_a@mail.ruМедицинский университет Южной Каролины, СШАСоединённые Штаты АмерикиMedical University of South Carolina, USAUnited StatesЭбботт Лабораториз, СШАСоединённые Штаты АмерикиAbbott, USAUnited StatesСанкт-Петербургская химико-фармацевтическая академияРоссияSaint Petersburg Chemical and Pharmaceutical AcademyRussian Federation20121208201294Педиатрическая фармакология4859Copyright © Симпсон К., Марлоу Н., Шоу Д., Рудакова А.В., 20122012Симпсон К., Марлоу Н., Шоу Д., Рудакова А.В.Simpson K., Marlow N., Shaw J., Rudakova А.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/302ювенильный идиопатический артритадалимумабанализ коэффициента «затраты/эффективность»juvenile idiopathic arthritisadalimumabcost-effectiveness analysisReferencesndersson G. B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol. 1999; 17: 367–374.Feldman D., Bernatsky S., Houde M. The incidence of juvenile rheumatoid arthritis in Quebec: a population data-based study. Pediatr. Rheumatol. Online J. 2009; 7: 20.Feldman D., Bernatsky S., Houde M. The incidence of juvenile rheumatoid arthritis in Quebec: a population data-based study. Pediatr. Rheumatol. Online J. 2009; 7: 20.Costa V., Ungar W. J., Hancock R. The use of biologic response modifiers in polyarticular-course juvenile ideopatic arthritis. Report No. 2010-01. January 11, 2010. http://pede.ccb.sickkids.ca/pde/task.jsp.Bernatsky S., Duffy C., Malleson P. et al. Economic impact of juvenile idiopathic arthritis. Arthritis and Rheumatism. 2007; 15: 44–48.Yagudina R.I., Zinchuk I.Yu., Kulikov A.Yu. Farmako eko no micheskii analiz primeneniya genno-injenernyh biologicheskih preparatov pri yuvenil'nom revmatoidnom artrite. Farmakoekonomika 2011; 4 (1): 18–23.Costa V., Ungar W. J., Hancock R. The use of biologic response modifiers in polyarticular-course juvenile ideopatic arthritis. Report № 2010-01. January 11, 2010. URL: http://www.pede.ccb.sickkids.ca/pde/task.jsp.Duarte-Salazar C., Guzman-Vaquez S., Soto-Molina H. et al. Disability impact on quality of life in Mexican adults with juvenileЯгудина Р. И., Зинчук И. Ю., Куликов А. Ю. Фармакоэкономический анализ применения генно-инженерных биологических препаратов при ювенильном ревматоидном артрите. Фармакоэкономика. 2011; 4 (1): 18–23.ideopatic arthritis and juvenile ankylosing spondylitis // Clin. Exp. Rheumatol. 2007; 25 (6):922–7.Duarte-Salazar C., Guzman-Vaquez S., Soto-Molina H. et al. Disability impact on quality of life in Mexican adults with juvenile ideopatic arthritis and juvenile ankylosing spondylitis. Clin. Exp. Rheumatol. 2007; 25 (6): 922–927.Osnes-Ringen H., Kvien T. K., Henriksen J.-E. et al. Orthopedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health related quality of life. Ann. Rheu. Dis. 2009; 68 (10): 1596–1601.Osnes-Ringen H., Kvien T. K., Henriksen J.-E. et al. Orthopedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health related quality of life. Ann. Rheu. Dis. 2008. Doi: 10.1136/ard.2008.096362.Weiss J., Ilowite N. Juvenile idiopathic arthritis. Pediatrics Clinics of North America 2005; 52: 413–442.Weiss J., Ilowite N. Juvenile idiopathic arthritis. Pediatrics Clinics of North America. 2005; 52: 413–442.Lovell D. J., Ruperto N., Goodman S. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Eng. J. Med. 2008; 359: 810–20.Lovell D. J., Ruperto N., Goodman S. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Eng. J. Med. 2008; 359: 810–820.Life tables for WHO Member States. Russian Federation. 2009. (www.who.int)Simpson K. N., Shaw J. W. Mapping the Childhood Health Assessment Questionnaire to the Health Utilities Index Mark 2 and Mark 3 in children with juvenile idiopathic arthritis [abstract]. Quality of Life Research. In press 2012.Prilojeniya k General'nomu tarifnomu soglasheniyu po tarifam na medicinskuyu pomosch' (medicinskie uslugi) i usloviyam oplaty medicinskoi pomoschi, okazyvaemoi v ramkah deistvuyuschei Territorial'noi programmy obyazatel'nogo medicinskogo strahovaniya grajdan Rossiiskoi Federacii v Sankt-Peterburge na 2011 g. (www.spboms.ru)Lam K., Young N., Marwaha J. et al. Revised version of the Childhood Health Assessment Questionnaire (CHAQ) is more sensitive and suffers less from a ceiling effect. Art Rheum. 2004; 51 (6): 881–889.Lundquist J., Kastang F., Kobelt G. The burden of rheumatoid arthritis and access to treatment: Health burden and cost. Eur. J. Health Econ. 2008; 8 (Suppl. 2): S49-S60.Packham J. C., Hall M. A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Functional outcome. Rheumatology. 2002; 41: 1428–1435.Simpson K.N., Shaw J.W. Mapping the Childhood Health Assessment Questionnaire to the Health Utilities Index Mark 2 andTorrance G. W., Feeny D. H., Furlong W. J. et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Medical Care. 1996; 34 (7): 702–722.Mark 3 in children with juvenile idiopathic arthritis [abstract]. Quality of Life Research. In press 2012.Lundquist J., Kastang F., Kobelt G. The burden of rheumatoid arthritis and access to treatment: Health burden and cost. Eur. J. Health Econ. 2008; 8 (Suppl. 2): 49–60.Andersson G.B. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence // Clin Exp Rheumatol. 1999; 17: 367–74.Life tables for WHO Member States. Russian Federation. 2009. URL: http://www.who.intBernatsky S., Duffy C., Malleson P., Feldman D.E., St. Pierre Y., Clarke A. Economic impact of juvenile idiopathic arthritis//Arthritis and Rheumatism. 2007; 15: 44–48.Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2011 г. URL: http://www.spboms.ruLam K., Young N., Marwaha j. et al. Revised version of the Childhood Health Assessment Questionnaire (CHAQ) are more sensitive and suffer less from a ceiling effect. Arthritis & Rheumatism. 2004; 51 (6); 881–889.Osnes-Ringen H., Kvien T. K., Henriksen J.-E. et al. Orthopedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health related quality of life. Ann. Rheu. Dis. 2009; 68 (10): 1596–1601.Packham J.C., Hall M.A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Functional outcome // Rheumatology. 2002; 41: 1428–1435.Torrance G.W., Feeny D.H., Furlong W.J., Barr R.D., Zhang Y., Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2 // Medical Care 1996; 34 (7): 702–722.Torrance G.W., Feeny D.H., Furlong W.J., Barr R.D., Zhang Y., Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2 // Medical Care 1996; 34 (7): 702–722.Lundquist J., Kastang F., Kobelt G. The burden of rheumatoid arthritis and access to treatment: hHealth burden and cost // Eur. J. Health Econ. 2008; 8 (Suppl. 2): S49-S60.Lundquist J., Kastang F., Kobelt G. The burden of rheumatoid arthritis and access to treatment: hHealth burden and cost // Eur. J. Health Econ. 2008; 8 (Suppl. 2): S49-S60.Duarte-Salazar C., Guzman-Vaquez S., Soto-Molina H. et al. Disability impact on quality of life in Mexican adults with juvenile ideopatic arthritis and juvenile ankylosing spondylitis // Clin. Exp. Rheumatol. 2007; 25 (6): 922–7.Duarte-Salazar C., Guzman-Vaquez S., Soto-Molina H. et al. Disability impact on quality of life in Mexican adults with juvenile ideopatic arthritis and juvenile ankylosing spondylitis // Clin. Exp. Rheumatol. 2007; 25 (6): 922–7.Osnes-Ringen H., Kvien T. K., Henriksen J.-E. et al. Orthopedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health related quality of life // Ann. Rheu. Dis. 2009; 68 (10): 1596–1601.Osnes-Ringen H., Kvien T. K., Henriksen J.-E. et al. Orthopedic surgery in 255 patients with inflammatory arthropathies: longitudinal effects on pain, physical function and health related quality of life // Ann. Rheu. Dis. 2009; 68 (10): 1596–1601.
The authors declare that there are no conflicts of interest present.